Breaking News

Over a month ago
Show Full Stories

X

To view all stories in expanded form, please subscribe.
Send Info
On The Fly
Fly Intel: Pre-market Movers » 09:12
12/09/21
12/09
09:12
12/09/21
09:12
CVS

CVS Health

$93.09 /

+0.16 (+0.17%)

, NVEI

Nuvei

$57.85 /

-39.23 (-40.41%)

, HRL

Hormel Foods

$42.79 /

+0.36 (+0.85%)

, CIEN

Ciena

$62.22 /

-0.745 (-1.18%)

, LQDT

Liquidity Services

$21.97 /

-0.12 (-0.54%)

, LEE

Lee Enterprises

$25.11 /

+0.5 (+2.03%)

, TRDA

Entrada Therapeutics

$20.87 /

-0.73 (-3.38%)

, GME

GameStop

$173.47 /

-4.21 (-2.37%)

, RENT

Rent The Runway

$11.46 /

-1.3 (-10.19%)

, ICPT

Intercept

$17.07 /

+0.14 (+0.83%)

, RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

, TGLS

Tecnoglass

$33.72 /

+0.965 (+2.95%)

Check out this morning's…

ShowHide Related Items >><<
TGLS Tecnoglass
$33.72 /

+0.965 (+2.95%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

NVEI Nuvei
$57.85 /

-39.23 (-40.41%)

LQDT Liquidity Services
$21.97 /

-0.12 (-0.54%)

LEE Lee Enterprises
$25.11 /

+0.5 (+2.03%)

ICPT Intercept
$17.07 /

+0.14 (+0.83%)

HRL Hormel Foods
$42.79 /

+0.36 (+0.85%)

GME GameStop
$173.47 /

-4.21 (-2.37%)

CVS CVS Health
$93.09 /

+0.16 (+0.17%)

CIEN Ciena
$62.22 /

-0.745 (-1.18%)

CVS CVS Health
$93.09 /

+0.16 (+0.17%)

12/01/21
Fly Intel: Top five analyst initiations
12/01/21 B. Riley
Identiv shares not fully pricing in prescription pill program, says B. Riley
12/01/21 Seaport Global
CVS Health initiated with a Buy at Seaport Global
11/10/21 Mizuho
CVS Health price target raised to $105 from $98 at Mizuho
NVEI Nuvei
$57.85 /

-39.23 (-40.41%)

12/09/21 RBC Capital
RBC Capital says points raised by short report on Nuvei 'not material' to thesis
12/09/21 National Bank
National Bank says Nuvei short report does not change investment thesis
12/09/21 BMO Capital
Nuvei upgraded to Outperform from Market Perform at BMO Capital
12/08/21 Cowen
Nuvei weakness on short report a buying opportunity, says Cowen
HRL Hormel Foods
$42.79 /

+0.36 (+0.85%)

10/08/21
Fly Intel: Top five analyst upgrades
10/08/21 JPMorgan
Hormel Foods upgraded to Neutral from Underweight at JPMorgan
09/03/21 Barclays
Hormel Foods price target lowered to $46 from $48 at Barclays
04/05/21 JPMorgan
BellRing, Hostess among JPMorgan's 'Own Now' names in food
CIEN Ciena
$62.22 /

-0.745 (-1.18%)

12/07/21 Jefferies
Jefferies sees Calix, Ciena among top plays on best Telco backdrop in 20 years
09/30/21
Ciena participates in a conference call with Benchmark
09/03/21 B. Riley
Ciena price target lowered to $51 from $53 at B. Riley
09/03/21 Barclays
Ciena price target lowered to $66 from $68 at Barclays
LQDT Liquidity Services
$21.97 /

-0.12 (-0.54%)

05/10/21 Barrington
Liquidity Services target raised to $30-$35 from $25 at Barrington
02/05/21 Barrington
Liquidity Services showing 'solid momentum' exiting Q1, says Barrington
02/04/21 Barrington
Liquidity Services price target raised to $25 from $20 at Barrington
LEE Lee Enterprises
$25.11 /

+0.5 (+2.03%)

TRDA Entrada Therapeutics
$20.87 /

-0.73 (-3.38%)

11/24/21 Evercore ISI
Evercore starts 'best-in-class next-gen DMD company' Entrada at Outperform
11/24/21 Evercore ISI
Entrada Therapeutics initiated with an Outperform at Evercore ISI
11/23/21
Fly Intel: Top five analyst initiations
11/23/21 Cowen
Entrada Therapeutics initiated with an Outperform at Cowen
GME GameStop
$173.47 /

-4.21 (-2.37%)

12/09/21 Wedbush
GameStop price target lowered to $45 from $50 at Wedbush
09/27/21 Ascendiant
Ascendiant keeps Sell rating on GameStop, cuts price target to $24
07/12/21 Ascendiant
GameStop price target raised to $25 from $10 at Ascendiant
06/28/21 Baird
Baird suspends GameStop rating pending business strategy clarity
RENT Rent The Runway
$11.46 /

-1.3 (-10.19%)

12/09/21 Morgan Stanley
Rent The Runway path to profitability still underestimated, says Morgan Stanley
12/09/21 Piper Sandler
Rent The Runway price target raised to $23 from $22 at Piper Sandler
11/22/21
Fly Intel: Top five analyst initiations
11/22/21 Morgan Stanley
Morgan Stanley starts 'underestimated' Rent The Runway with an Overweight
ICPT Intercept
$17.07 /

+0.14 (+0.83%)

12/09/21 Piper Sandler
Intercept made 'smart move' in withdrawing application, says Piper Sandler
11/04/21 B. Riley
Intercept price target raised to $25 from $22 at B. Riley
08/20/21
Fly Intel: Top five analyst downgrades
08/20/21 Goldman Sachs
Intercept downgraded to Sell from Neutral at Goldman Sachs
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/09/21 Goldman Sachs
Reata Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs
12/09/21 Cantor Fitzgerald
Reata Pharmaceuticals price target lowered to $68 from $112 at Cantor Fitzgerald
12/09/21 Baird
Baird downgrades Reata with 'almost zero chance' of approval
12/09/21 Barclays
Reata Pharmaceuticals price target lowered to $43 from $180 at Barclays
TGLS Tecnoglass
$33.72 /

+0.965 (+2.95%)

11/09/21 B. Riley
Tecnoglass upgraded to Buy on market share gains at B. Riley
11/09/21 Raymond James
Tecnoglass price target raised to $35 from $26 at Raymond James
11/09/21 Baird
Tecnoglass price target raised to $38 from $32 at Baird
11/09/21 B. Riley
Tecnoglass upgraded to Buy from Neutral at B. Riley
TRDA Entrada Therapeutics
$20.87 /

-0.73 (-3.38%)

TGLS Tecnoglass
$33.72 /

+0.965 (+2.95%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RENT Rent The Runway
$11.46 /

-1.3 (-10.19%)

NVEI Nuvei
$57.85 /

-39.23 (-40.41%)

LQDT Liquidity Services
$21.97 /

-0.12 (-0.54%)

LEE Lee Enterprises
$25.11 /

+0.5 (+2.03%)

ICPT Intercept
$17.07 /

+0.14 (+0.83%)

HRL Hormel Foods
$42.79 /

+0.36 (+0.85%)

GME GameStop
$173.47 /

-4.21 (-2.37%)

CVS CVS Health
$93.09 /

+0.16 (+0.17%)

CIEN Ciena
$62.22 /

-0.745 (-1.18%)

  • 29
    Oct
  • 27
    Oct
  • 06
    Oct
NVEI Nuvei
$57.85 /

-39.23 (-40.41%)

LEE Lee Enterprises
$25.11 /

+0.5 (+2.03%)

GME GameStop
$173.47 /

-4.21 (-2.37%)

CVS CVS Health
$93.09 /

+0.16 (+0.17%)

TRDA Entrada Therapeutics
$20.87 /

-0.73 (-3.38%)

TGLS Tecnoglass
$33.72 /

+0.965 (+2.95%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RENT Rent The Runway
$11.46 /

-1.3 (-10.19%)

NVEI Nuvei
$57.85 /

-39.23 (-40.41%)

ICPT Intercept
$17.07 /

+0.14 (+0.83%)

HRL Hormel Foods
$42.79 /

+0.36 (+0.85%)

GME GameStop
$173.47 /

-4.21 (-2.37%)

CVS CVS Health
$93.09 /

+0.16 (+0.17%)

TGLS Tecnoglass
$33.72 /

+0.965 (+2.95%)

RENT Rent The Runway
$11.46 /

-1.3 (-10.19%)

NVEI Nuvei
$57.85 /

-39.23 (-40.41%)

LEE Lee Enterprises
$25.11 /

+0.5 (+2.03%)

GME GameStop
$173.47 /

-4.21 (-2.37%)

CVS CVS Health
$93.09 /

+0.16 (+0.17%)

CIEN Ciena
$62.22 /

-0.745 (-1.18%)

Downgrade
Reata Pharmaceuticals downgraded to Neutral from Buy at Goldman Sachs » 08:56
12/09/21
12/09
08:56
12/09/21
08:56
RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

Goldman Sachs analyst…

Goldman Sachs analyst Salveen Richter downgraded Reata Pharmaceuticals to Neutral from Buy with a price target of $39, down from $244, following the unanimous negative vote from an FDA panel with respect to the risk-benefit profile of the company's lead drug bardoxolone in patients with Alport syndrome. The analyst sees negative implications for the Phase 3 program of bardoxolone in autosomal dominant polycystic kidney disease, Reata's "key value driver," but notes its second drug omaveloxolone in Friedreich's ataxia "provides a valuation floor."

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/09/21 Cantor Fitzgerald
Reata Pharmaceuticals price target lowered to $68 from $112 at Cantor Fitzgerald
12/09/21 Baird
Baird downgrades Reata with 'almost zero chance' of approval
12/09/21 Barclays
Reata Pharmaceuticals price target lowered to $43 from $180 at Barclays
12/09/21 SVB Leerink
Reata Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

Recommendations
Reata Pharmaceuticals price target lowered to $68 from $112 at Cantor Fitzgerald » 07:20
12/09/21
12/09
07:20
12/09/21
07:20
RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

Cantor Fitzgerald analyst…

Cantor Fitzgerald analyst Charles Duncan lowered the firm's price target on Reata Pharmaceuticals to $68 from $112 and keeps an Overweight rating on the shares. On December 8, the FDA hosted an advisory committee meeting to discuss Reata's NDA submission for bardoxolone for the treatment of Alport syndrome. With the committee's 13 members unanimously voting "no" on the question of whether "the provided evidence demonstrate that bardoxolone methyl is effective in slowing the progression of chronic kidney disease in Alport syndrome and that its benefits outweigh its risks," Duncan believes the likelihood of a positive review by/on the February 25, 2022 PDUFA target action date has been reduced to near-zero, the analyst tells investors in a research note.

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/09/21 Baird
Baird downgrades Reata with 'almost zero chance' of approval
12/09/21 Barclays
Reata Pharmaceuticals price target lowered to $43 from $180 at Barclays
12/09/21 SVB Leerink
Reata Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
12/09/21 Baird
Reata Pharmaceuticals downgraded to Neutral from Outperform at Baird
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

Downgrade
Baird downgrades Reata with 'almost zero chance' of approval » 06:36
12/09/21
12/09
06:36
12/09/21
06:36
RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

Baird analyst Brian…

Baird analyst Brian Skorney downgraded Reata Pharmaceuticals to Neutral from Outperform with a price target of $37, down from $110. The FDA panel discounted all of Reata's arguments, "leaving almost zero chance" of bardoxolone approval based on the CARDINAL study, Skorney tells investors in a research note. There may be ways to salvage this indication without another multi-year study, but "these are long shots" given the FDA's posture towards bardoxolone, says the analyst. Skorney sees a "multitude of questions" following the FDA review and Reata's relationship with the agency.

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/09/21 Barclays
Reata Pharmaceuticals price target lowered to $43 from $180 at Barclays
12/09/21 SVB Leerink
Reata Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
12/09/21 Baird
Reata Pharmaceuticals downgraded to Neutral from Outperform at Baird
12/07/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

Recommendations
Reata Pharmaceuticals price target lowered to $43 from $180 at Barclays » 06:23
12/09/21
12/09
06:23
12/09/21
06:23
RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

Barclays analyst Carter…

Barclays analyst Carter Gould lowered the firm's price target on Reata Pharmaceuticals to $43 from $180 and keeps an Overweight rating on the shares. The negative FDA panel votes "leaves little hope" for bardoxolone methyl, Gould tells investors in a research note.

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/09/21 SVB Leerink
Reata Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink
12/09/21 Baird
Reata Pharmaceuticals downgraded to Neutral from Outperform at Baird
12/07/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/07/21 Cantor Fitzgerald
Reata price target lowered to $112 from $230 at Cantor Fitzgerald
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

Downgrade
Reata Pharmaceuticals downgraded to Market Perform from Outperform at SVB Leerink » 06:19
12/09/21
12/09
06:19
12/09/21
06:19
RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

SVB Leerink analyst…

SVB Leerink analyst Joseph Schwartz downgraded Reata Pharmaceuticals to Market Perform from Outperform with a $35 price target.

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/09/21 Baird
Reata Pharmaceuticals downgraded to Neutral from Outperform at Baird
12/07/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/07/21 Cantor Fitzgerald
Reata price target lowered to $112 from $230 at Cantor Fitzgerald
12/06/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

Downgrade
Reata Pharmaceuticals downgraded to Neutral from Outperform at Baird » 05:40
12/09/21
12/09
05:40
12/09/21
05:40
RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

Baird analyst Brian…

Baird analyst Brian Skorney downgraded Reata Pharmaceuticals to Neutral from Outperform with a price target of $37, down from $110.

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/07/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/07/21 Cantor Fitzgerald
Reata price target lowered to $112 from $230 at Cantor Fitzgerald
12/06/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/06/21 Stifel
FDA took 'rather negative tone' in review of Reata's bardoxolone, says Stifel
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

Hot Stocks
Reata Pharmaceuticals down 35% after resumption of trading » 19:18
12/08/21
12/08
19:18
12/08/21
19:18
RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

Shares of Reata…

Shares of Reata Pharmaceuticals are down 35% afterhours at $35.50 after the stock resumed trading following its announced outcome of FDA AdCom meeting on bardoxolone. The company had stated that the Advisory Committee voted NO on the question of whether the provided evidence demonstrated that bardoxolone is effective in slowing the progression of CKD in patients with Alport syndrome and that its benefits outweigh its risks.

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/07/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/07/21 Cantor Fitzgerald
Reata price target lowered to $112 from $230 at Cantor Fitzgerald
12/06/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/06/21 Stifel
FDA took 'rather negative tone' in review of Reata's bardoxolone, says Stifel
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

Hot Stocks
Reata Pharmaceuticals announces outcome of FDA meeting on bardoxolone » 17:54
12/08/21
12/08
17:54
12/08/21
17:54
RETA

Reata Pharmaceuticals

$54.45 /

-0.07 (-0.13%)

Reata Pharmaceuticals…

Reata Pharmaceuticals announced the outcome of the U.S. FDA Cardiovascular and Renal Drugs Advisory Committee meeting on bardoxolone methyl for the treatment of patients with chronic kidney disease caused by Alport syndrome. The Committee voted no on the question of whether the provided evidence demonstrated that bardoxolone is effective in slowing the progression of CKD in patients with Alport syndrome and that its benefits outweigh its risks. "We are disappointed with today's outcome of the Committee's vote regarding bardoxolone, an investigational drug with a novel mechanism of action," said Warren Huff, Reata's President and CEO. "We believe the scientific evidence supports bardoxolone approval in the U.S. for CKD in patients with Alport syndrome, which is one of the most rapidly progressive forms of CKD. We will continue to work with the FDA to answer any questions they may have." While the FDA is not required to follow the committee's vote, the agency considers the committee's recommendations when making its decision. Reata will continue to work closely with the agency to provide additional information and data until the upcoming Prescription Drug User-Fee Act date of February 25, 2022.

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

12/07/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/07/21 Cantor Fitzgerald
Reata price target lowered to $112 from $230 at Cantor Fitzgerald
12/06/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/06/21 Stifel
FDA took 'rather negative tone' in review of Reata's bardoxolone, says Stifel
RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

RETA Reata Pharmaceuticals
$54.45 /

-0.07 (-0.13%)

Conference/Events
FDA Cardiovascular and Renal Drugs Advisory Committee Meeting » 09:25
12/08/21
12/08
09:25
12/08/21
09:25
RETA

Reata Pharmaceuticals

$54.45 /

+5.56 (+11.37%)

The Committee discusses…

The Committee discusses Reata Pharmaceuticals New Drug Application (NDA) 215484, for the Nrf2 activator, bardoxolone methyl capsules which is used to slow the progression of chronic kidney disease caused by Alport syndrome in patients 12 years of age and older in a virtual meeting being held on December 8 at 9:30 am. Webcast Link

ShowHide Related Items >><<
RETA Reata Pharmaceuticals
$54.45 /

+5.56 (+11.37%)

RETA Reata Pharmaceuticals
$54.45 /

+5.56 (+11.37%)

12/07/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/07/21 Cantor Fitzgerald
Reata price target lowered to $112 from $230 at Cantor Fitzgerald
12/06/21 Baird
Reata Pharmaceuticals price target lowered to $110 from $212 at Baird
12/06/21 Stifel
FDA took 'rather negative tone' in review of Reata's bardoxolone, says Stifel
RETA Reata Pharmaceuticals
$54.45 /

+5.56 (+11.37%)

RETA Reata Pharmaceuticals
$54.45 /

+5.56 (+11.37%)

Get Full Fly Access

Breaking market intelligence sent straight to you
Our team of experts analyze every news story and filter out the noise to deliver real-time market moving news.
Up-to-date information on important industry events
Get real-time updates on events that are moving the market—from conferences and calls to syndicate announcements.
News focused on the companies in your portfolio
Create up to 12 portfolios with 150 stocks each, and see how active they are in market news.